Procter & Gamble Health Sells Mumbai Property, Books ₹32 Crore Profit

Procter & Gamble Health has recorded a profit of ₹32.00 crore from the sale of its properties in Mumbai. The company's annual sales for the fiscal year ending March 31, 2026, stood at ₹934.17 crore.

The Sale Details

Procter & Gamble Health Limited announced the sale of its properties located in Mumbai on April 30, 2026. The transaction is expected to yield a profit of approximately ₹32.00 crore. This disclosure was made in compliance with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Strategic Asset Sale

The sale represents a strategic move to monetize non-core assets. Such transactions allow companies to unlock capital, strengthen their financial position, and reallocate resources without disrupting primary business operations. For P&G Health, this brings in additional profit and cash reserves.

About P&G Health

Procter & Gamble Health Ltd, formerly known as Merck Limited, is a significant player in India's pharmaceutical and consumer healthcare market. It focuses on manufacturing and marketing healthcare products, including vitamins, minerals, and supplements (VMS), under brands like Neurobion, Polybion, Evion, Nasivion, Livogen, and Seven Seas. The company became part of the global P&G conglomerate after its acquisition in 2018.

Immediate Impact

This property sale will boost the company's cash reserves and potentially enhance its profitability for the current reporting period. Shareholders can see this as an efficient use of non-core assets to generate value.

Industry Peers

Procter & Gamble Health operates within the competitive Indian pharmaceutical and healthcare sector. Its peers include companies like Marksans Pharma Ltd., Sanofi India Ltd., and Ajanta Pharma Ltd., among others in the VMS and broader healthcare markets.

Key Company Figures

• Fiscal Year 2026 Sales: ₹934.17 crore
• Market Capitalisation (as of April 15, 2026): $879 million (approximately ₹7,300 crore)

Investor Watchlist

Investors will likely monitor how P&G Health plans to utilize the proceeds from this sale. Key areas to track include any impact on debt levels, future investments in its core VMS and pharmaceutical business, or potential enhancements to shareholder returns through dividends or buybacks.